- $46.31m
- $54.64m
- $27.04m
- 34
- 58
- 60
- 49
Annual income statement for DarioHealth, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 7.58 | 20.5 | 27.7 | 20.4 | 27 |
| Cost of Revenue | |||||
| Gross Profit | 2.51 | 3.96 | 9.65 | 5.98 | 13.3 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 37.5 | 97 | 88.9 | 81.4 | 89.1 |
| Operating Profit | -29.9 | -76.5 | -61.3 | -61.1 | -62 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -29.4 | -76.7 | -62.2 | -59.4 | -44.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -29.4 | -76.8 | -62.2 | -59.4 | -42.7 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -29.4 | -76.8 | -62.2 | -59.4 | -42.7 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -33.1 | -78.8 | -63.8 | -63.5 | -41 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -111 | -94.3 | -51.6 | -42.5 | -15.1 |